915 related articles for article (PubMed ID: 24419272)
1. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.
Ashby CR; Kehne JH; Bartoszyk GD; Renda MJ; Athanasiou M; Pierz KA; Seyfried CA
Eur J Pharmacol; 2013 Aug; 714(1-3):359-65. PubMed ID: 23872377
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
Page ME; Cryan JF; Sullivan A; Dalvi A; Saucy B; Manning DR; Lucki I
J Pharmacol Exp Ther; 2002 Sep; 302(3):1220-7. PubMed ID: 12183683
[TBL] [Abstract][Full Text] [Related]
5. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus.
Roberts C; Hagan JJ; Bartoszyk GD; Kew JN
Eur J Pharmacol; 2005 Jul; 517(1-2):59-63. PubMed ID: 15978574
[TBL] [Abstract][Full Text] [Related]
6. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
Dawson LA; Watson JM
CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors.
Tordera RM; Monge A; Del Río J; Lasheras B
Eur J Pharmacol; 2002 May; 442(1-2):63-71. PubMed ID: 12020683
[TBL] [Abstract][Full Text] [Related]
8. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat.
De Vry J; Schreiber R; Melon C; Dalmus M; Jentzsch KR
Eur Neuropsychopharmacol; 2004 Dec; 14(6):487-95. PubMed ID: 15589388
[TBL] [Abstract][Full Text] [Related]
9. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.
Bartoszyk GD; Hegenbart R; Ziegler H
Eur J Pharmacol; 1997 Mar; 322(2-3):147-53. PubMed ID: 9098681
[TBL] [Abstract][Full Text] [Related]
10. Role of 5-HT(1A) receptors in fluoxetine-induced lordosis inhibition.
Guptarak J; Sarkar J; Hiegel C; Uphouse L
Horm Behav; 2010 Jul; 58(2):290-6. PubMed ID: 20223238
[TBL] [Abstract][Full Text] [Related]
11. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus.
Bermack JE; Haddjeri N; Debonnel G
J Pharmacol Exp Ther; 2004 Aug; 310(2):578-83. PubMed ID: 15044555
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram.
Stenfors C; Yu H; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):222-32. PubMed ID: 11218075
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex.
Dawson LA; Nguyen HQ; Smith DL; Schechter LE
J Psychopharmacol; 2002 Jun; 16(2):145-52. PubMed ID: 12095073
[TBL] [Abstract][Full Text] [Related]
14. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.
Invernizzi R; Bramante M; Samanin R
Pharmacol Biochem Behav; 1996 May; 54(1):143-7. PubMed ID: 8728551
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats.
Oosting RS; Chan JS; Olivier B; Banerjee P; Choi YK; Tarazi F
Psychopharmacology (Berl); 2016 Mar; 233(6):1025-34. PubMed ID: 26758283
[TBL] [Abstract][Full Text] [Related]
16. Chronic fluoxetine-induced desensitization of 5-HT1A and 5-HT1B autoreceptors: regional differences and effects of WAY-100635.
Newman ME; Shalom G; Ran A; Gur E; Van de Kar LD
Eur J Pharmacol; 2004 Feb; 486(1):25-30. PubMed ID: 14751404
[TBL] [Abstract][Full Text] [Related]
17. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions.
Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
Neuroscience; 1999; 93(4):1251-62. PubMed ID: 10501449
[TBL] [Abstract][Full Text] [Related]
18. Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors.
Hervás I; Artigas F
Eur J Pharmacol; 1998 Sep; 358(1):9-18. PubMed ID: 9809863
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor.
Stahl SM
CNS Spectr; 2014 Apr; 19(2):105-9. PubMed ID: 24673885
[TBL] [Abstract][Full Text] [Related]
20. The mechanism by which the selective 5-HT1A receptor antagonist S-(-) UH 301 produces head-twitches in mice.
Darmani NA; Reeves SL
Pharmacol Biochem Behav; 1996 Sep; 55(1):1-10. PubMed ID: 8870031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
